К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 7 min

Neuroendocrine tumours: how they are treated and why the Ki-67 grade changes everything

Neuroendocrine tumours (NET) and carcinomas: G1–G3 grade by Ki-67, DOTA PET, somatostatin analogues, lutetium radionuclide therapy, everolimus, chemotherapy and treatment of liver metastases.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Neuroendocrine tumours (NET) develop from cells that produce hormones and are located in different organs: small bowel, pancreas, lungs, stomach, appendix, rectum. This is a very diverse group. Some tumours grow for years and allow people to live for decades with correct treatment, while others behave aggressively and need chemotherapy.

In this article I explain how to read the report (grade, Ki-67), which tests are needed, which treatments exist and when each is chosen. It is not a quick topic: there are many variants, and it helps to understand the logic.

The main question: NET or NEC, and which grade

The report usually states:

  • differentiation: well-differentiated neuroendocrine tumour (NET) or poorly differentiated neuroendocrine carcinoma (NEC);
  • grade: G1, G2 or G3 by Ki-67 index and mitotic count (Ki-67, grade).
Grade Ki-67 (guide) How it usually behaves
G1 below 3% Slow growth, may stay unchanged for years
G2 3–20% Intermediate rate of growth
G3 (NET) above 20%, but well differentiated Grows faster but is treated differently from carcinoma
NEC usually above 20% (often much higher) Aggressive, treated like small cell cancer

The difference between NET G3 and NEC matters because the treatment regimens differ. If your report says only "neuroendocrine tumour" without grade and Ki-67, ask for clarification: how to read a pathology report, slide review. More on terms: neuroendocrine tumour.

Hormonally active and inactive tumours

Some tumours produce hormones and cause symptoms:

  • carcinoid syndrome (more often with liver metastases of small bowel tumours): flushing, diarrhoea, wheezing, damage to heart valves;
  • other syndromes in pancreatic tumours: for example hypoglycaemia in insulinoma.

Many tumours are hormonally inactive and are found by chance or by pressing on organs.

Investigations

  • CT and MRI of the abdomen (MRI of the liver is especially important);
  • DOTA PET/CT (68Ga-DOTATATE or similar) labelled to somatostatin receptors: the main method for staging and assessing suitability for radionuclide therapy (what PET-CT shows);
  • chromogranin A and, when carcinoid syndrome is suspected, urinary 5-HIAA: useful, but should be interpreted with care (for example proton pump inhibitors raise chromogranin) (tumour markers);
  • in carcinoid syndrome, echocardiography to assess valves;
  • endoscopy and, if needed, endoscopic ultrasound.

Treatment of localised NET

Surgery is the main method when the tumour can be removed. The extent depends on site:

  • small NETs of the stomach, appendix or rectum are sometimes removed endoscopically or with a small operation;
  • small bowel tumours are removed with a segment of bowel and mesentery;
  • pancreatic tumours are removed with part of the gland, and small ones are sometimes watched;
  • lung tumours (typical and atypical carcinoid) are removed surgically.

Additional treatment after surgery is usually not needed for G1 and G2. For G3 the decision is individual.

Before surgery in carcinoid syndrome octreotide is given to prevent a dangerous "carcinoid crisis".

Advanced NET G1–G2

When the disease cannot be fully removed by surgery, one chooses from several methods, often in sequence.

Method Purpose
Somatostatin analogues (octreotide, lanreotide) Control symptoms and slow the growth of slowly growing tumours, given every 4 weeks
Lutetium-177 radionuclide therapy For progression on analogues if DOTA PET shows uptake of the label; well studied in small bowel NET
Everolimus Tablets; used in NETs of the pancreas, gastrointestinal tract and lung
Sunitinib Tablets; for pancreatic NET
Capecitabine + temozolomide (CAPTEM) For G2 pancreatic NET with progression or large volume
Local liver treatment Resection, ablation, embolisation when liver metastases are the main problem
Telotristat Reduces diarrhoea in carcinoid syndrome, where registered

More on drugs: capecitabine, targeted therapy. On liver metastases: liver metastases.

The order of drugs depends on the primary site, grade, volume and growth rate, symptoms and DOTA PET results. There is no effective "universal" order, so it is sensible to discuss the plan at a tumour board with a NET specialist.

NET G3 and neuroendocrine carcinoma

  • NEC: the main method is platinum with etoposide chemotherapy (as in small cell lung cancer: small cell lung cancer). In the second line irinotecan- or oxaliplatin-based regimens (FOLFIRI, FOLFOX) and others are used. The response is often good but frequently temporary.
  • NET G3: the choice between chemotherapy (platinum with etoposide, or CAPTEM) and methods used in G2 (for example radionuclide therapy) depends on Ki-67, DOTA PET and the clinical picture.

Immunotherapy in NET/NEC is not yet standard, but in selected situations (for example MSI-H) it is possible: MSI and dMMR.

Side effects

  • Somatostatin analogues: abdominal pain, fatty stools, bloating, gallstones with long-term use; there may be a lump at the injection site.
  • Lutetium-177: nausea on the day of the infusion, temporary reduction in blood counts; precautions for other people for a few days (as the centre advises).
  • Everolimus: mouth sores (stomatitis), rash, raised sugar and cholesterol, non-infectious lung inflammation.
  • Sunitinib: raised blood pressure, hand-foot syndrome (hand-foot syndrome), diarrhoea.
  • Platinum with etoposide: low white cells, nausea, hair loss (fever on chemotherapy).

Diarrhoea can be both a symptom of the tumour and a side effect of treatment, and the cause should be clarified: diarrhoea during treatment.

Follow-up

In NET G1–G2 after surgery follow-up is long (years and decades), because recurrence can be late. It includes examinations, CT or MRI, sometimes DOTA PET and laboratory tests. Frequency depends on grade and stage.

Nutrition and lifestyle

In carcinoid syndrome flushing can be provoked by alcohol, spicy food and stress. With diarrhoea, fluid and electrolytes need control. If the tumour is in the pancreas or the pancreas was operated on, enzyme replacement may be needed. More: nutrition during chemotherapy.

What to ask your doctor

  • Is this a NET or NEC? What are the grade and Ki-67?
  • Was DOTA PET done?
  • Is the tumour hormonally active and are somatostatin analogues needed?
  • What is the sequence of treatment at progression?
  • Is radionuclide therapy suitable for me?
  • What do we do about liver metastases?
  • How often and with what will we follow up?

When to seek urgent help

  • severe flushing with a fall in blood pressure and difficulty breathing (possible carcinoid crisis);
  • severe abdominal pain, vomiting, bloating and no stool (possible obstruction);
  • severe weakness, sweating, confusion (hypoglycaemia is possible in insulinoma);
  • temperature of 38 °C or above on chemotherapy;
  • black stool or blood in the stool;
  • swelling and pain in one leg (see thrombosis in cancer).

Can I get a second opinion

Yes, and for neuroendocrine tumours it is especially useful, because there are many options and doctors' experience is uneven. Reasons: no grade or Ki-67, NET G3 not distinguished from NEC, DOTA PET not done, chemotherapy offered at once for a slowly growing tumour or a choice among several methods. Prepare the pathology, CT, MRI, DOTA PET (if done) and summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: pancreatic cancer.

Sources

  1. Gastrointestinal Neuroendocrine Tumors Treatment (PDQ) — National Cancer Institute
  2. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ) — National Cancer Institute
  3. ESMO Clinical Practice Guidelines — ESMO
  4. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  5. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.